Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Polymer mediated transport of the Hsp90 inhibitor LB76, a polar cyclic peptide, produces an Hsp90 cellular phenotype.

Rahimi MN, Foster HG, Farazi SN, Chapman R, McAlpine SR.

Chem Commun (Camb). 2019 Apr 11;55(31):4515-4518. doi: 10.1039/c9cc00890j.

PMID:
30920570
2.

Nanoparticles for Bioapplications: Study of the Cytotoxicity of Water Dispersible CdSe(S) and CdSe(S)/ZnO Quantum Dots.

Mirnajafizadeh F, Ramsey D, McAlpine S, Wang F, Stride JA.

Nanomaterials (Basel). 2019 Mar 20;9(3). pii: E465. doi: 10.3390/nano9030465.

3.

Delivering bioactive cyclic peptides that target Hsp90 as prodrugs.

Huo Y, Buckton LK, Bennett JL, Smith EC, Byrne FL, Hoehn KL, Rahimi MN, McAlpine SR.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):728-739. doi: 10.1080/14756366.2019.1580276.

4.

Protein-protein inhibitor designed de novo to target the MEEVD region on the C-terminus of Hsp90 and block co-chaperone activity.

Rahimi MN, McAlpine SR.

Chem Commun (Camb). 2019 Jan 15;55(6):846-849. doi: 10.1039/c8cc07576j.

PMID:
30575826
5.

Synthesis and Structure-Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90.

Rahimi MN, Buckton LK, Zaiter SS, Kho J, Chan V, Guo A, Konesan J, Kwon S, Lam LKO, Lawler MF, Leong M, Moldovan GD, Neale DA, Thornton G, McAlpine SR.

ACS Med Chem Lett. 2017 Dec 13;9(2):73-77. doi: 10.1021/acsmedchemlett.7b00310. eCollection 2018 Feb 8.

6.

Designing de Novo Small Molecules That Control Heat Shock Protein 70 (Hsp70) and Heat Shock Organizing Protein (HOP) within the Chaperone Protein-Folding Machinery.

Zaiter SS, Huo Y, Tiew FY, Gestwicki JE, McAlpine SR.

J Med Chem. 2019 Jan 24;62(2):742-761. doi: 10.1021/acs.jmedchem.8b01436. Epub 2018 Dec 20.

PMID:
30507174
7.

Hsp90 Mediates Membrane Deformation and Exosome Release.

Lauwers E, Wang YC, Gallardo R, Van der Kant R, Michiels E, Swerts J, Baatsen P, Zaiter SS, McAlpine SR, Gounko NV, Rousseau F, Schymkowitz J, Verstreken P.

Mol Cell. 2018 Sep 6;71(5):689-702.e9. doi: 10.1016/j.molcel.2018.07.016.

PMID:
30193096
8.

Improving the Cell Permeability of Polar Cyclic Peptides by Replacing Residues with Alkylated Amino Acids, Asparagines, and d-Amino Acids.

Buckton LK, McAlpine SR.

Org Lett. 2018 Feb 2;20(3):506-509. doi: 10.1021/acs.orglett.7b03363. Epub 2018 Jan 24.

PMID:
29364690
9.

RITA Mimics: Synthesis and Mechanistic Evaluation of Asymmetric Linked Trithiazoles.

Pietkiewicz AL, Zhang Y, Rahimi MN, Stramandinoli M, Teusner M, McAlpine SR.

ACS Med Chem Lett. 2017 Mar 6;8(4):401-406. doi: 10.1021/acsmedchemlett.6b00488. eCollection 2017 Apr 13.

10.

How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?

Wang Y, Koay YC, McAlpine SR.

ChemMedChem. 2017 Mar 7;12(5):353-357. doi: 10.1002/cmdc.201600595. Epub 2017 Feb 27.

PMID:
28139075
11.

Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.

Wang Y, Koay YC, McAlpine SR.

Chemistry. 2017 Feb 10;23(9):2010-2013. doi: 10.1002/chem.201604807. Epub 2017 Jan 20.

PMID:
27862436
12.

Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.

Koay YC, Wahyudi H, McAlpine SR.

Chemistry. 2016 Dec 19;22(51):18572-18582. doi: 10.1002/chem.201603464. Epub 2016 Nov 11.

PMID:
27859703
13.

A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.

Armstrong HK, Koay YC, Irani S, Das R, Nassar ZD; Australian Prostate Cancer BioResource, Selth LA, Centenera MM, McAlpine SR, Butler LM.

Prostate. 2016 Dec;76(16):1546-1559. doi: 10.1002/pros.23239. Epub 2016 Aug 16.

PMID:
27526951
14.

Hydrothermal synthesis of highly luminescent blue-emitting ZnSe(S) quantum dots exhibiting low toxicity.

Mirnajafizadeh F, Ramsey D, McAlpine S, Wang F, Reece P, Stride JA.

Mater Sci Eng C Mater Biol Appl. 2016 Jul 1;64:167-172. doi: 10.1016/j.msec.2016.03.061. Epub 2016 Mar 23.

PMID:
27127041
15.

Hitting a Moving Target: How Does an N-Methyl Group Impact Biological Activity?

Koay YC, Richardson NL, Zaiter SS, Kho J, Nguyen SY, Tran DH, Lee KW, Buckton LK, McAlpine SR.

ChemMedChem. 2016 Apr 19;11(8):881-92. doi: 10.1002/cmdc.201500572. Epub 2016 Jan 25.

PMID:
26805515
16.

Synthesis of the Natural Product Marthiapeptide A.

Zhang Y, Islam MA, McAlpine SR.

Org Lett. 2015 Nov 6;17(21):5149-51. doi: 10.1021/acs.orglett.5b02574. Epub 2015 Oct 15.

PMID:
26469351
17.

Regulating the master regulator: Controlling heat shock factor 1 as a chemotherapy approach.

McConnell JR, Buckton LK, McAlpine SR.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3409-14. doi: 10.1016/j.bmcl.2015.06.052. Epub 2015 Jun 20. Review.

PMID:
26164188
18.

Nuclear factor κB-inducing kinase activation as a mechanism of pancreatic β cell failure in obesity.

Malle EK, Zammit NW, Walters SN, Koay YC, Wu J, Tan BM, Villanueva JE, Brink R, Loudovaris T, Cantley J, McAlpine SR, Hesselson D, Grey ST.

J Exp Med. 2015 Jul 27;212(8):1239-54. doi: 10.1084/jem.20150218. Epub 2015 Jun 29.

19.

Predicting the unpredictable: Recent structure-activity studies on peptide-based macrocycles.

Wahyudi H, McAlpine SR.

Bioorg Chem. 2015 Jun;60:74-97. doi: 10.1016/j.bioorg.2015.04.009. Epub 2015 May 1. Review.

PMID:
25973779
20.

Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts.

Toscan CE, Rahimi M, Bhadbhade M, Pickford R, McAlpine SR, Lock RB.

Org Biomol Chem. 2015 Jun 14;13(22):6299-312. doi: 10.1039/c5ob00779h.

PMID:
25967739

Supplemental Content

Loading ...
Support Center